DHA’s $41M Wafermine Award Faces U.S. Manufacturing Licensing Risk
The Defense Health Agency awarded Singapore-based iX Biopharma nearly $41 million in February 2026 to develop Wafermine, a sublingual ketamine product for battlefield pain relief. The award is not an open competition, but U.S. deployment could be delayed by pending emergency-use authorization and a Nevada pharmacy license required by proposed manufacturer Orion Specialty Labs.